FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2092307522> ?p ?o ?g. }

• W2092307522 endingPage "14" @default.
• W2092307522 startingPage "1" @default.
• W2092307522 abstract "Prostate cancer (PCa) is one of the most common cancers in men. Each year approximately 543,000 new cases are reported worldwide, and the disease kills 200,000 (mostly older men) in developed countries. The existing treatment approaches and surgical intervention have not been able to effectively manage this dreaded cancer and, therefore, continuing efforts are ongoing to explore novel targets and strategies for the management of PCa. The activity of polo-like kinase 1 (Plk1) is elevated in tissues and cells with a high mitotic index, including cancer cells. An increasing body of evidence suggests that the level of Plk1 expression has prognostic value for predicting outcomes in patients with some cancers. A close correlation between Plk1 expression and carcinogenesis has been documented. However, the role of Plk1 in PCa is not known. We propagated a hypothesis that Plk1 inhibition will result in elimination of human PCa cells via a mitotic arrest followed by apoptosis (1). To define the role of Plk1 in PCa, we used the technique of RNA silencing via small interfering RNA (siRNA). First, using a series of human prostate carcinoma cells and normal human prostate epithelial (PrEC) cells, we assessed Plk1 levels in PCa. Immunoblot analyses clearly showed a significant expression of Plk1 in LNCaP, DU145, and PC3 human PCa cells. Interestingly, Plk1 was not detectable in normal PrEC cells. Next, we transfected the PCa cells with Plk 1 siRNA, which resulted in a significant inhibition in Plk1 protein in all PCa cells. Plk1 depletion resulted in a decrease in cell viability and induction of apoptosis in PCa cells but had no appreciable effect in normal PrEC cells. Our data also demonstrated that Plk1 siRNA transfection of PCa cells resulted in 1) a mitotic cell cycle arrest, 2) failure of cytokinesis, and 3) defects in centrosome integrity and maturation. Thus, our study suggested that 1) Plk1 plays a critical role in the process of PCa development and 2) gene therapeutic approaches aimed at Plk1 or the pharmacological inhibitors of Plk1 may be developed for the management of PCa." @default.
• W2092307522 created "2016-06-24" @default.
• W2092307522 creator A5028352583 @default.
• W2092307522 creator A5045348217 @default.
• W2092307522 date "2005-01-20" @default.
• W2092307522 modified "2023-09-23" @default.
• W2092307522 title "Silencing of polo‐like kinase (Plk) 1 via siRNA causes induction of apoptosis and impairment of mitosis machinery in human prostate cancer cells: implications for the treatment of prostate cancer" @default.
• W2092307522 cites W1560426558 @default.
• W2092307522 cites W1820990168 @default.
• W2092307522 cites W1968868084 @default.
• W2092307522 cites W1980057048 @default.
• W2092307522 cites W2004981153 @default.
• W2092307522 cites W2020411912 @default.
• W2092307522 cites W2020516698 @default.
• W2092307522 cites W2027042262 @default.
• W2092307522 cites W2050329134 @default.
• W2092307522 cites W2051163818 @default.
• W2092307522 cites W2053738387 @default.
• W2092307522 cites W2058680827 @default.
• W2092307522 cites W2068788664 @default.
• W2092307522 cites W2074056525 @default.
• W2092307522 cites W2080321631 @default.
• W2092307522 cites W2082087067 @default.
• W2092307522 cites W2109903344 @default.
• W2092307522 cites W2162311131 @default.
• W2092307522 cites W2167003908 @default.
• W2092307522 cites W2172117494 @default.
• W2092307522 cites W2319415470 @default.
• W2092307522 doi "https://doi.org/10.1096/fj.04-2910fje" @default.
• W2092307522 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15661849" @default.
• W2092307522 hasPublicationYear "2005" @default.
• W2092307522 type Work @default.
• W2092307522 sameAs 2092307522 @default.
• W2092307522 citedByCount "124" @default.
• W2092307522 countsByYear W20923075222012 @default.
• W2092307522 countsByYear W20923075222013 @default.
• W2092307522 countsByYear W20923075222014 @default.
• W2092307522 countsByYear W20923075222015 @default.
• W2092307522 countsByYear W20923075222016 @default.
• W2092307522 countsByYear W20923075222017 @default.
• W2092307522 countsByYear W20923075222018 @default.
• W2092307522 countsByYear W20923075222019 @default.
• W2092307522 countsByYear W20923075222020 @default.
• W2092307522 countsByYear W20923075222021 @default.
• W2092307522 countsByYear W20923075222022 @default.
• W2092307522 countsByYear W20923075222023 @default.
• W2092307522 crossrefType "journal-article" @default.
• W2092307522 hasAuthorship W2092307522A5028352583 @default.
• W2092307522 hasAuthorship W2092307522A5045348217 @default.
• W2092307522 hasConcept C104317684 @default.
• W2092307522 hasConcept C119056186 @default.
• W2092307522 hasConcept C121608353 @default.
• W2092307522 hasConcept C126322002 @default.
• W2092307522 hasConcept C146276462 @default.
• W2092307522 hasConcept C22615655 @default.
• W2092307522 hasConcept C2776438761 @default.
• W2092307522 hasConcept C2779723316 @default.
• W2092307522 hasConcept C2780192828 @default.
• W2092307522 hasConcept C29537977 @default.
• W2092307522 hasConcept C502942594 @default.
• W2092307522 hasConcept C54009773 @default.
• W2092307522 hasConcept C54355233 @default.
• W2092307522 hasConcept C71924100 @default.
• W2092307522 hasConcept C81885089 @default.
• W2092307522 hasConcept C84815855 @default.
• W2092307522 hasConcept C86803240 @default.
• W2092307522 hasConcept C93304396 @default.
• W2092307522 hasConcept C95444343 @default.
• W2092307522 hasConcept C96232424 @default.
• W2092307522 hasConceptScore W2092307522C104317684 @default.
• W2092307522 hasConceptScore W2092307522C119056186 @default.
• W2092307522 hasConceptScore W2092307522C121608353 @default.
• W2092307522 hasConceptScore W2092307522C126322002 @default.
• W2092307522 hasConceptScore W2092307522C146276462 @default.
• W2092307522 hasConceptScore W2092307522C22615655 @default.
• W2092307522 hasConceptScore W2092307522C2776438761 @default.
• W2092307522 hasConceptScore W2092307522C2779723316 @default.
• W2092307522 hasConceptScore W2092307522C2780192828 @default.
• W2092307522 hasConceptScore W2092307522C29537977 @default.
• W2092307522 hasConceptScore W2092307522C502942594 @default.
• W2092307522 hasConceptScore W2092307522C54009773 @default.
• W2092307522 hasConceptScore W2092307522C54355233 @default.
• W2092307522 hasConceptScore W2092307522C71924100 @default.
• W2092307522 hasConceptScore W2092307522C81885089 @default.
• W2092307522 hasConceptScore W2092307522C84815855 @default.
• W2092307522 hasConceptScore W2092307522C86803240 @default.
• W2092307522 hasConceptScore W2092307522C93304396 @default.
• W2092307522 hasConceptScore W2092307522C95444343 @default.
• W2092307522 hasConceptScore W2092307522C96232424 @default.
• W2092307522 hasFunder F4320306078 @default.
• W2092307522 hasIssue "6" @default.
• W2092307522 hasLocation W20923075221 @default.
• W2092307522 hasLocation W20923075222 @default.
• W2092307522 hasOpenAccess W2092307522 @default.
• W2092307522 hasPrimaryLocation W20923075221 @default.
• W2092307522 hasRelatedWork W2062196172 @default.
• W2092307522 hasRelatedWork W2092307522 @default.
• W2092307522 hasRelatedWork W2118642421 @default.

• next